Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TransMedics (TMDX) Cash & Equivalents (2018 - 2025)

Historic Cash & Equivalents for TransMedics (TMDX) over the last 8 years, with Q3 2025 value amounting to $466.2 million.

  • TransMedics' Cash & Equivalents rose 4123.25% to $466.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $466.2 million, marking a year-over-year increase of 4123.25%. This contributed to the annual value of $336.6 million for FY2024, which is 1473.16% down from last year.
  • Latest data reveals that TransMedics reported Cash & Equivalents of $466.2 million as of Q3 2025, which was up 4123.25% from $400.6 million recorded in Q2 2025.
  • TransMedics' Cash & Equivalents' 5-year high stood at $582.2 million during Q2 2023, with a 5-year trough of $17.9 million in Q1 2022.
  • Its 5-year average for Cash & Equivalents is $247.9 million, with a median of $310.1 million in 2025.
  • In the last 5 years, TransMedics' Cash & Equivalents plummeted by 5051.22% in 2021 and then soared by 181604.69% in 2023.
  • Quarter analysis of 5 years shows TransMedics' Cash & Equivalents stood at $25.6 million in 2021, then surged by 686.48% to $201.2 million in 2022, then skyrocketed by 96.25% to $394.8 million in 2023, then dropped by 14.73% to $336.6 million in 2024, then soared by 38.48% to $466.2 million in 2025.
  • Its Cash & Equivalents stands at $466.2 million for Q3 2025, versus $400.6 million for Q2 2025 and $310.1 million for Q1 2025.